Explore the words cloud of the MaRiA project. It provides you a very rough idea of what is the project "MaRiA" about.
The following table provides information about the project.
QUEEN MARY UNIVERSITY OF LONDON
|Coordinator Country||United Kingdom [UK]|
|Total cost||195˙454 €|
|EC max contribution||195˙454 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2017-09-21 to 2020-02-21|
Take a look of project's partnership.
|1||QUEEN MARY UNIVERSITY OF LONDON||UK (LONDON)||coordinator||195˙454.00|
The proposed work will investigate the regulation of pro-resolving lipid mediators (LM) by pathobionts and dysbiotic microbiota in rheumatoid arthritis (RA).
RA is a chronic inflammatory disease with considerable socioeconomic impact. Most treatment options carry severe side effects including immunosuppression. Recent studies found associations between RA and dysbiosis of the microbiota, with the underlying mechanisms leading to this dysbiosis remaining of interest. In addition, I recently found that in both mice during pathobiont-driven inflammatory arthritis and in plasma from patients with RA the levels of a novel family of host protective LM, termed n-3 docosapentaenoic acid-derived Resolvins (RvDn-3 DPA), were significantly altered.
The novel hypothesis of this action is that pathobionts and pathobiont-induced gut-dysbiosis trigger local inflammatory responses and impair the production of RvDn-3 DPA, resulting in exacerbation and chronicity of local inflammation.
This novel hypothesis will be addressed using a multi-pronged approach to:
1) Characterise the role of Porphyromonas gingivalis and Prevotella copri in regulating RvDn-3 DPA, local inflammation and their effects on intestinal microbiota and gut barrier function.
2) Assess the regulation of inflammatory arthritis and RvDn-3 DPA by RA patients’ microbiota.
3) Establish the protective actions of RvDn-3 DPA in pathobiont-driven inflammatory arthritis.
This will provide insights into mechanisms of pathobiont- and dysbiotic microbiota-triggered arthritic inflammation, the regulation of tissue LM profiles and identify potential novel diagnostic markers for early RA-detection. In addition, this work will establish the therapeutic potential of RvDn-3 DPA in regulating exacerbated inflammation and dysbiosis in inflammatory arthritis, providing novel therapeutic opportunities for RA treatment.
|year||authors and title||journal||last update|
E. MuÃ±oz-Atienza, M.B. Flak, J. Sirr, N.A. Paramonov, J. Aduse-Opoku, C. Pitzalis, M.A. Curtis
The P. gingivalis Autocitrullinome Is Not a Target for ACPA in Early Rheumatoid Arthritis
published pages: 456-462, ISSN: 0022-0345, DOI: 10.1177/0022034519898144
|Journal of Dental Research 99/4||2020-04-15|
Magdalena B. Flak, Romain A. Colas, EstefanÃa MuÃ±oz-Atienza, Michael A. Curtis, Jesmond Dalli, Costantino Pitzalis
Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis
published pages: , ISSN: 2379-3708, DOI: 10.1172/jci.insight.125191
|JCI Insight 4/13||2020-04-15|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MARIA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MARIA" are provided by the European Opendata Portal: CORDIS opendata.
CuInGaSe Nanowires Under the SunRead More
New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.Read More
Landscapes of Loss: Mapping the Affective Experience of Deforestation Among Diverse Social Groups in the South American ChacoRead More